Lineage Cell Therapeutics, Inc. (LCTX)
XASE:LCTX
Want to see LCTX full AI Analyst Report?
LCTX Stock Chart & Stats
$1.71
-$0.04(-6.64%)
At close: 4:00 PM EST
$1.71
-$0.04(-6.64%)
Day’s Range― - ―
52-Week Range$0.64 - $2.09
Previous CloseN/A
Volume522.43K
Average Volume (3M)1.29M
Market Cap
$331.57M
Enterprise Value$298.02M
Total Cash (Recent Filing)$53.38M
Total Debt (Recent Filing)$2.39M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Aug 06, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding249,298,300
10 Day Avg. Volume1,186,971
30 Day Avg. Volume1,290,512
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)8.63
Price to Sales (P/S)26.40
P/FCF Ratio-19.77
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue20.17
Enterprise Value/Gross Profit20.58
Enterprise Value/Ebitda-6.19
Forecast
1Y Price Target
$6.25Price Target Upside265.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.07
Revenue Forecast (FY)$15.63M
Bulls Say, Bears Say
Bulls Say
Manufacturing ScalabilityAlloSCOPE manufacturing enables production of large quantities of uniform cells from a single master cell bank, addressing donor scarcity and supporting a scalable commercial pathway.
Ocular Efficacy DataOpRegen long-term observations have shown reversal of geographic atrophy and measurable vision improvement, indicating potential to restore function beyond therapies that only slow disease progression.
Pipeline Depth And Business DevelopmentTechnical advances across multiple pipeline programs expand long-term product potential and increase attractiveness for business development deals and non-dilutive funding.
Bears Say
Clinical Trial And Financing RiskFailed or inconclusive clinical trials combined with difficulty securing sufficient funding could prevent the stock from reaching analyst targets, reflecting the high-risk profile of regenerative medicine development.
Operating Loss PressureReported operating losses indicate ongoing development expenses that will require additional capital and could lead to further dilution or valuation pressure if fundraising challenges arise.
Slow Patient EnrollmentThe OPC1 DOSED study faces slow, staggered patient enrollment because eligible patients are hard to find and dosing logistics are complex, which could delay clinical progress and milestone timing.
Lineage Therap News
LCTX FAQ
What was Lineage Cell Therapeutics, Inc.’s price range in the past 12 months?
Lineage Cell Therapeutics, Inc. lowest stock price was $0.64 and its highest was $2.09 in the past 12 months.
What is Lineage Cell Therapeutics, Inc.’s market cap?
Lineage Cell Therapeutics, Inc.’s market cap is $331.57M.
When is Lineage Cell Therapeutics, Inc.’s upcoming earnings report date?
Lineage Cell Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 67 days.
How were Lineage Cell Therapeutics, Inc.’s earnings last quarter?
Lineage Cell Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of -$0.02 by -$0.01.
Is Lineage Cell Therapeutics, Inc. overvalued?
According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued.
Does Lineage Cell Therapeutics, Inc. pay dividends?
Lineage Cell Therapeutics, Inc. does not currently pay dividends.
What is Lineage Cell Therapeutics, Inc.’s EPS estimate?
Lineage Cell Therapeutics, Inc.’s EPS estimate is -0.02.
How many shares outstanding does Lineage Cell Therapeutics, Inc. have?
Lineage Cell Therapeutics, Inc. has 249,298,300 shares outstanding.
What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?
Lineage Cell Therapeutics, Inc. reported an EPS of -$0.03 in its last earnings report, missing expectations of -$0.02. Following the earnings report the stock price went down -3.759%.
Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LCTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lineage Therap Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.25 (265.50% Upside)
$6.25 (265.50% Upside)
Blogger Sentiment
Bullish
LCTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 6.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $24.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 15.2%
Last 30 Days ▲ 15.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
93.87%
12-Months-Change
Fundamentals
Return on Equity
-152.10%
Trailing 12-Months
Asset Growth
-1.99%
Trailing 12-Months
Company Description
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
LCTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial scientific and operational progress across Lineage's manufacturing platform and pipeline: AlloSCOPE advances, the launch and initial preclinical success of COR1, ILT1 scale-up milestones, completed engineering runs for ReSonance, device performance and site expansion for OPC1, SAB and clinical leadership hires, and partner validation for OpRegen (including multi-year vision durability and expansion to 17 sites). Financials show modest revenue, rising R&D and operating expenses, and a larger net loss year-over-year, but a cash runway into 2028 plus potential warrant proceeds and sizeable contingent Roche/Genentech milestones mitigate near-term funding concerns. Program risks remain — notably islet scale-up technical challenges, timing uncertainty tied to partners (OpRegen), and some earlier-stage setbacks (photoreceptor IP change, CIRM non-award) — however the volume and quality of operational and scientific milestones reported suggest progress materially outweighs current financial and program risks.View all LCTX earnings summariesLCTX Stock 12 Month Forecast
Average Price Target
$6.25
▲(265.50% Upside)
Technical Analysis
Amarin
―
Tvardi Therapeutics
―
DBV Technologies SA - American
―
4D Molecular Therapeutics
―
Aura Biosciences Inc
―
Ownership Overview
13.98% Insiders
4.52% Mutual Funds
27.10% Other Institutional Investors
50.40% Public Companies and
Individual Investors